Differential Roles for IL ‐ 4Rα and IL ‐ 13Rα1 in Immune Cell Infiltration and Epithelial Remodeling in Experimental Eosinophilic Gastritis
Allergy · 18.06.2026
DOI: 10.1111/all.70420 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, online erschienen am 18.06.2026. Verfasst von Anish Dsilva und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Microbiology and Immunology, Gray Faculty of Medical and Health Sciences, Tel-Aviv University, Israel. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Israel Science Foundation, United States Israel Binational Science Foundation, Food Allergy Fund.
Abstract (Originalsprache)
Rationale
Eosinophilic gastritis (EoG) is a chronic inflammatory disease characterized by infiltration of eosinophils and mast cells, epithelial remodeling, and fibrosis. Although EoG is increasingly recognized as a distinct type 2 inflammatory disease, the cellular and molecular events that drive disease pathogenesis remain poorly understood. This is due in part to the absence of robust and physiologically relevant experimental models that recapitulate human disease Methods Experimental EoG was induced in wild‐type and Il13ra1 −/− mice by repeated intragastric oxazolone challenges in skin‐sensitized mice. IL‐4Rα was neutralized using antibodies. Gastric histopathology was determined by H&E, anti‐Ki67, chloroacetate esterase, and anti‐MBP staining. Gastric RNA was subjected to RNA sequencing.
Results
Experimental EoG resulted in robust gastric eosinophilia, mastocytosis, epithelial remodeling, and subepithelial fibrosis. Transcriptomic profiling of gastric tissue revealed broad upregulation of type 2 cytokine and epithelial‐remodeling genes, including Il4ra , Il4i1, Ccl5, Muc4, Mmp10 , Mcpt1/2, Areg, Pparg , and Tff2 . The transcriptome profile of experimental EoG was markedly distinct from that of experimental EoE despite both models being initiated by oxazolone, suggesting that identical inflammatory triggers elicit tissue‐specific and context‐dependent transcriptional programs. Blockade of IL‐4Rα signaling abrogated both eosinophil and mast cell infiltration and attenuated epithelial remodeling, whereas genetic deletion of Il13ra1 selectively suppressed epithelial remodeling without affecting inflammatory cell recruitment.
Conclusion
These findings establish experimental EoG as a robust model for dissecting the cellular and molecular mechanisms driving gastric type 2 inflammation. They further define receptor‐specific roles for IL‐4Rα and IL‐13Rα1 in coordinating immune infiltration and epithelial remodeling in EoG.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Microbiology and Immunology, Gray Faculty of Medical and Health Sciences, Tel-Aviv University, Israel.
- The Roberts-Guthman Chair in Immunopharmacology, Tel-Aviv University, Israel.
ORCID-Profile: Ariel Munitz
Förderung
- Israel Science Foundation
- United States Israel Binational Science Foundation
- Food Allergy Fund
- Israel Cancer Research Fund
- Israel Cancer Association
Zitieren
APA
Dsilva, A., Sharma, S., Barakey, S., Wagner, A., Keisar, A., Bar-On, T., Itan, M., & Munitz, A. (2026). Differential Roles for IL ‐ 4Rα and IL ‐ 13Rα1 in Immune Cell Infiltration and Epithelial Remodeling in Experimental Eosinophilic Gastritis. Allergy. https://doi.org/10.1111/all.70420
Vancouver
Dsilva A, Sharma S, Barakey S, Wagner A, Keisar A, Bar-On T, et al. Differential Roles for IL ‐ 4Rα and IL ‐ 13Rα1 in Immune Cell Infiltration and Epithelial Remodeling in Experimental Eosinophilic Gastritis. Allergy. 2026. doi:10.1111/all.70420
BibTeX
@article{Dsilva2026,
author = {Dsilva, Anish and Sharma, Shraddha and Barakey, Shireen and Wagner, Ariel and Keisar, Alice and Bar-On, Tali and Itan, Michal and Munitz, Ariel},
title = {Differential Roles for IL ‐ 4Rα and IL ‐ 13Rα1 in Immune Cell Infiltration and Epithelial Remodeling in Experimental Eosinophilic Gastritis},
journal = {Allergy},
year = {2026},
doi = {10.1111/all.70420}
}
EUVIMED